A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: HER-2 Positive Breast Cancer|Malignant Neoplasm of Breast
Interventions: DRUG: Lapatinib, Caelyx
Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori